| Australian Mines Limited (AUZ) ORDINARY FULLY PAID |
Materials |
$31 |
Cleansing notice
|
10 Jul 2025 9:16AM |
$0.008 |
$0.015 |
risen by
87.50%
|
|
| Mindax Limited (MDX) ORDINARY FULLY PAID |
Materials |
$73 |
Secondary Trading Notice
|
10 Jul 2025 9:16AM |
$0.063 |
$0.031 |
fallen by
50.79%
|
|
| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$174 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
10 Jul 2025 9:16AM |
$0.865 |
$1.325 |
risen by
53.18%
|
|
VTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers operations up to 30 June 2023.
- Continued progress at the North Stanmore REE Project with positive drilling results.
- Company is advancing exploration and development of rare earths projects.
- Ongoing efforts to optimize expenditure and manage cash flows.
- Reported changes in Board and management during the quarter.
- Detailed Appendix 5B Cash Flow Report attached, summarizing exploration and corporate expenditure.
- Strategic initiatives and project portfolio strengthening efforts highlighted.
- Company maintains focus on rare earth elements as core business.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$66 |
Positive feedback from FDA on strategy to lift clinical hold
|
10 Jul 2025 9:15AM |
$0.160 |
$0.094 |
fallen by
41.25%
|
|
NUZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Neurizon Therapeutics Limited (NUZ) received positive feedback from the FDA on its strategy to lift a clinical hold.
- The clinical hold affected NUZ's investigational new drug (IND) application for a neurological disorder therapy.
- The company submitted a comprehensive response addressing FDA concerns and proposing risk mitigation strategies.
- FDA acknowledged the proposed modifications and offered a path forward for resuming clinical development.
- NUZ can resume its clinical program once recommended changes are implemented.
- The feedback represents a significant milestone for Neurizon Therapeutics and advances its mission in neurological therapeutics.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vulcan Energy Resources Limited (VUL) ORDINARY FULLY PAID |
Materials |
$1,563 |
Trading Halt
|
10 Jul 2025 9:15AM |
$4.000 |
$3.270 |
fallen by
18.25%
|
|
VUL - Price-sensitive ASX Announcement
Full Release
Key Points
- Vulcan Energy Resources Limited requested a trading halt on 24 August 2023.
- The trading halt is pending an announcement related to a capital raising.
- VUL requested that the halt remain until normal trading resumes on 28 August 2023 or until the relevant announcement is made.
- ASX granted the trading halt to ensure the market is fully informed.
- The trading halt is a standard procedure for material announcements affecting share prices.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Mines Limited (AUZ) ORDINARY FULLY PAID |
Materials |
$31 |
Application for quotation of securities - AUZ
|
10 Jul 2025 9:14AM |
$0.008 |
$0.015 |
risen by
87.50%
|
|
| Graincorp Limited (GNC) ORDINARY FULLY PAID CLASS A |
Consumer Staple |
$1,356 |
Update - Notification of buy-back - GNC
|
10 Jul 2025 9:14AM |
$7.540 |
$6.100 |
fallen by
19.10%
|
|
| Aura Energy Limited (AEE) ORDINARY FULLY PAID |
Energy |
$135 |
Appointment of Ousmane Mamoudou Kane to Aura Energy Board
|
10 Jul 2025 9:13AM |
$0.145 |
$0.135 |
fallen by
6.90%
|
|
| KKR Credit Income Fund (KKC) ORDINARY UNITS FULLY PAID |
Financials |
$677 |
Net Tangible Asset Backing
|
10 Jul 2025 9:12AM |
$2.350 |
$2.100 |
fallen by
10.64%
|
|
| Carnegie Clean Energy Limited (CCE) ORDINARY FULLY PAID |
Utilities |
$26 |
DGWA Appointed European Advisor
|
10 Jul 2025 9:11AM |
$0.053 |
$0.064 |
risen by
20.75%
|
|
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$619 |
Regulatory and Business Update
|
10 Jul 2025 9:10AM |
$1.555 |
$1.930 |
risen by
24.12%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Announcement date is 30 April 2024
- Imricor is advancing MRI-compatible cardiac ablation system technology
- Significant regulatory progress, including European and Australian approvals
- Preparation and engagement with FDA for US market entry are ongoing
- Increased procedure volume and new hospital site launches in Europe
- Expansion into new clinical sites and partnerships to drive adoption
- Participation in clinical trials and registries to support market access and reimbursement
- Ongoing focus on commercialization and scaling of operations
- Financial update includes cash position and strategic planning for future funding
- Forward-looking statements highlight market opportunity and growth potential
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Rare Earths Limited (AR3) ORDINARY FULLY PAID |
Materials |
$42 |
AR3 adds to Overland with uranium potential from surface
|
10 Jul 2025 9:10AM |
$0.054 |
$0.165 |
risen by
205.56%
|
|
AR3 - Price-sensitive ASX Announcement
Full Release
Key Points
- AR3 has secured the Wyacca tenement, adding significant uranium potential to its Overland Project.
- Historical exploration identified shallow uranium mineralization at Wyacca in the 1970s and 1980s.
- The new tenement is located in South Australia and complements AR3’s existing rare earth element portfolio.
- AR3 plans further drilling and evaluation to assess both uranium and rare earth resources.
- The company aims to develop Overland as a sustainable rare earth and uranium project.
- Stakeholder engagement and environmental considerations will be key focuses moving forward.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Osmond Resources Limited (OSM) ORDINARY FULLY PAID |
Materials |
$73 |
Quarterly Activities and Cashflow Report
|
10 Jul 2025 9:09AM |
$0.850 |
$0.530 |
fallen by
37.65%
|
|
OSM - Price-sensitive ASX Announcement
Full Release
Key Points
- Osmond Resources Limited released its Quarterly Activities and Cashflow Report for Q1 2023.
- Exploration activities were focused on Sandford, Tallangatta, Yumbarra, Coorabie, and Fowler projects.
- Progress included geophysical surveys, soil sampling, mapping, and target generation, notably at Sandford and Tallangatta.
- Corporate highlights include compliance with ASX Listing Rule 5.3.5 and disclosure of related party payments.
- Cash and cash equivalents at the end of the quarter were $3.84 million.
- Planned activities for the next quarter focus on further exploration and investment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Stepchange Holdings Limited (STH) ORDINARY FULLY PAID |
Information Technology |
$19 |
Listing Presentation - July 2025
|
10 Jul 2025 9:09AM |
n/a |
$0.115 |
n/a
|
|
| Pacgold Limited (PGO) ORDINARY FULLY PAID |
Materials |
$54 |
White Lion Prospect Geophysical Survey
|
10 Jul 2025 9:09AM |
$0.063 |
$0.125 |
risen by
98.41%
|
|
PGO - Price-sensitive ASX Announcement
Full Release
Key Points
- Pacgold Limited has initiated a high-resolution ground magnetic survey at the White Lion Prospect.
- The survey is designed to refine drill targets and improve geological understanding of gold mineralization.
- White Lion Prospect is part of the Alice River Gold Project in North Queensland.
- The announcement details the survey methodology and the geological significance of the area.
- Historical exploration and previous drill results at White Lion are summarized, indicating gold potential.
- The company outlines improvements in exploration technology and data interpretation.
- Pacgold's broader strategy focuses on systematic exploration and leveraging advanced geophysics.
- White Lion is strategically located near other key prospects within the Alice River Project.
- The survey is expected to enhance targeting accuracy for future drilling campaigns.
- Pacgold stresses the importance of integrating geophysical data in their exploration programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Stepchange Holdings Limited (STH) ORDINARY FULLY PAID |
Information Technology |
$19 |
Completion of successful IPO and Business Update
|
10 Jul 2025 9:08AM |
n/a |
$0.115 |
n/a
|
|
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$414 |
RC220 Human Ethics Approvals Received in Hong Kong
|
10 Jul 2025 9:07AM |
$1.170 |
$2.280 |
risen by
94.87%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Race Oncology Ltd received human ethics approvals for RC220 clinical trials in Hong Kong.
- The approvals allow for the initiation of Phase 1 studies in healthy volunteers.
- The trials will assess safety, tolerability, and pharmacokinetics of RC220.
- This marks Race Oncology’s entry into clinical development in the Asia-Pacific region.
- The approvals represent a significant advancement in the company’s oncology pipeline.
- These milestones are integral to Race Oncology’s broader drug development and commercial plans.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Washington H. Soul Pattinson and Co. Limited (SOL) ORDINARY FULLY PAID |
Financials |
$14,437 |
Notification of cessation of securities - SOL
|
10 Jul 2025 9:07AM |
$41.750 |
$38.000 |
fallen by
8.98%
|
|
| American West Metals Limited (AW1) ORDINARY FULLY PAID |
Materials |
$49 |
Storm Large Scale Copper Potential Reaffirmed
|
10 Jul 2025 9:07AM |
$0.039 |
$0.049 |
risen by
25.64%
|
|
AW1 - Price-sensitive ASX Announcement
Full Release
Key Points
- American West Metals Limited has reaffirmed the large-scale copper potential at the Storm Project in Nunavut, Canada.
- Recent drilling has confirmed high-grade copper zones and extensive mineralisation outside the current resource areas.
- A broader technical review supports the resource growth opportunity at Storm.
- Several high-priority drill targets have been identified for the upcoming exploration season.
- Regional exploration has outlined additional copper prospects and geophysical anomalies.
- AW1 plans to continue advancing the Storm Project with expanded exploration and development activities.
- The company’s strategy is underpinned by robust geological data and significant resource upside.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| New World Resources Limited (NWC) ORDINARY FULLY PAID |
Materials |
- |
Second Supplementary Bidder's Statement
|
10 Jul 2025 9:06AM |
$0.065 |
$0.067 |
risen by
3.08%
|
|
NWC - Price-sensitive ASX Announcement
Full Release
Key Points
- Second Supplementary Bidder's Statement issued by New World Resources Limited (NWC) regarding its off-market bid for Alto Metals Limited.
- Dated 20 June 2024 and supplements previous bidder statements.
- Updates and clarifies offer terms, conditions, and procedures for Alto shareholders.
- Describes NWC’s intentions regarding Alto’s assets, operations, and management if the bid is successful.
- Provides updated information on NWC’s share price, recent performance, and capital structure.
- Discloses additional risk factors and matters relevant to Alto shareholders considering acceptance.
- Details the legal and procedural framework for the offer and acceptance process.
- Reaffirms NWC's strategic rationale for the acquisition and intended benefits.
- Includes amendments and new information not contained in previous statements.
- Ensures compliance with regulatory requirements and aims to provide full transparency to Alto shareholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Decidr AI Industries Ltd (DAI) ORDINARY FULLY PAID |
Consumer Staple |
$122 |
New and Existing Decidr Partnerships Update
|
10 Jul 2025 9:06AM |
$0.485 |
$0.380 |
fallen by
21.65%
|
|
| Spectur Limited (SP3) ORDINARY FULLY PAID |
Information Technology |
$5 |
Cash Balance at 30 June 2025 & FY25 Guidance Update
|
10 Jul 2025 9:05AM |
$0.014 |
$0.013 |
fallen by
7.14%
|
|
SP3 - Price-sensitive ASX Announcement
Full Release
Key Points
- SP3 platform has progressed commercially with key milestones achieved.
- Production and supply chain improvements have been implemented to support scalability.
- Revenue growth is forecasted for FY25, reflecting increased demand for SP3 and other products.
- Spectur targets a stronger cash balance at 30 June 2025, aiming for operational sustainability.
- The company anticipates breakeven or positive cash flow in FY25, depending on sales execution.
- Guidance is based on current contracted and forecasted sales, with further upside if additional opportunities are converted.
- Spectur continues to focus on cost control and operational efficiencies to support its financial goals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$224 |
Orthocell Announces First US Remplir Sales Revenue
|
10 Jul 2025 9:03AM |
$1.220 |
$0.825 |
fallen by
32.38%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Orthocell Limited achieved its first U.S. sales revenue from Remplir.
- Remplir is an innovative device for tendon repair surgeries.
- The sales milestone follows the product's U.S. commercial launch.
- Orthocell is partnering with distributors and key opinion leaders in the U.S.
- The announcement underscores significant commercial and clinical interest.
- Remplir's entry into the U.S. market is part of a broader international strategy.
- The company anticipates further growth and expansion opportunities for Remplir.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Green360 Technologies Limited (GT3) ORDINARY FULLY PAID |
Materials |
$50 |
Bulk Calcining - High Purity Kaolin to Produce Metakaolin
|
10 Jul 2025 9:01AM |
$0.038 |
$0.041 |
risen by
7.89%
|
|
| Beforepay Group Limited (B4P) ORDINARY FULLY PAID |
Financials |
$83 |
Change in substantial holding
|
10 Jul 2025 8:58AM |
$1.670 |
$1.660 |
fallen by
0.60%
|
|
Call 1300 880 160
Start a chat
Schedule a call
